English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/220140
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Mycophenolate Mofetil in C3 glomerulopathy and pathogenic drivers of the disease

AuthorsCaravaca-Fontán, Fernando; Díaz-Encarnación, Montserrat M.; Lucientes, Laura; Cavero, Teresa; Cabello-Chaves, Virginia; Ariceta, Gema; Quintana, Luis F.; Marco, Helena; Barros, Xoana; Ramos, Natalia; Rodríguez-Mendiola, Nuria; Cruz, Sonia; Fernández-Juárez, Gema; Rodríguez, Adela; Pérez de José, Ana; Rabasco, Cristina; Rodado, Raquel; Fernández, Loreto; Pérez Gómez, Vanessa; Ávila, Ana; Bravo, Luis; Lumbreras, Javier; Allende, Natalia; Sánchez de la Nieta, María Dolores; Rodríguez, Eva; Olea, Teresa; Melgosa, Marta; Huerta, Ana; Miquel, Rosa; Mon, Carmen; Fraga, Gloria; de Lorenzo, Alberto; Cano-Megías, Marta; González, Fayna; Shabaka, Amir; López-Rubio, María Esperanza; Fenollosa, María Ángeles; Martín-Penagos, L.; Da Silva, Lara; Alonso Titos, Juana; Rodríguez de Córdoba, Santiago ; Goicoechea de Jorge, Elena ; Praga, Manuel
KeywordsAlternative complement pathway
C3 glomerulopathy
Mycophenolate mofetil
Issue Date21-Aug-2020
PublisherAmerican Society of Nephrology
CitationCJASN 15 (2020)
AbstractBACKGROUND AND OBJECTIVES: C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components. Previous studies showed that treatment with corticosteroids plus mycophenolate mofetil (MMF) was associated with improved outcomes, although the genetic profile of these patients was not systematically analyzed. This study aims to analyze the main determinants of disease progression and response to this therapeutic regimen.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective, multicenter, observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients diagnosed with C3 glomerulopathy (n=81) or dense deposit disease (n=16) between January 1995 and March 2018 were enrolled. Multivariable and propensity score matching analyses were used to evaluate the association of clinical and genetic factors with response to treatment with corticosteroids and MMF as measured by proportion of patients with disease remission and kidney survival (status free of kidney failure).
RESULTS: The study group comprised 97 patients (84% C3 glomerulopathy, 16% dense deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this treatment was associated with a higher rate of remission and lower probability of kidney failure (79% and 14%, respectively) compared with patients treated with other immunosuppressives (24% and 59%, respectively), or ecluzimab (33% and 67%, respectively), or conservative management (18% and 65%, respectively). The therapeutic superiority of corticosteroids plus MMF was observed both in patients with complement abnormalities and with autoantibodies. However, patients with pathogenic variants in complement genes only achieved partial remission, whereas complete remissions were common among patients with autoantibody-mediated forms. The main determinant of no remission was baseline proteinuria. Relapses occurred after treatment discontinuation in 33% of the patients who had achieved remission with corticosteroids plus MMF, and a longer treatment length of MMF was associated with a lower risk of relapse.
CONCLUSIONS: The beneficial response to corticosteroids plus MMF treatment in C3 glomerulopathy appears independent of the pathogenic drivers analyzed in this study.
Description12 p.-4 fig.-4 tab.
Publisher version (URL)https://doi.org/10.2215/CJN.15241219
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdfRestringido15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.